T4	total-participants 564 567	305
T5	intervention-participants 618 620	34
T6	intervention-participants 631 633	20
T7	intervention-participants 680 682	55
T8	control-participants 740 743	196
T2	control 721 734	control group
T9	outcome 893 980	fibrosis, breast edema, retraction, ulceration, lymphedema, hyperpigmentation, and pain
T10	outcome 1011 1025	telangiectases
T11	outcome 1122 1130	fibrosis
T12	iv-bin-percent 1156 1159	5.9
T13	iv-bin-percent 1167 1171	37.5
T14	iv-bin-percent 1179 1185	18.4 %
T15	cv-bin-percent 1201 1207	38.2 %
T16	outcome 1250 1264	telangiectases
T17	iv-bin-percent 1293 1296	0 %
T18	iv-bin-percent 1312 1318	17.5 %
T19	iv-bin-percent 1341 1347	17.7 %
T20	outcome 1376 1397	higher grade toxicity
T23	outcome 1495 1506	recurrences
T1	intervention 30 64	intraoperative radiotherapy (IORT)
T3	outcome 1235 1245	at 3 years
T21	iv-cont-median 1545 1554	40 months
T22	cv-cont-median 1567 1576	42 months
